Tracking Cathie Wood: Increased position in blockchain company SECZ by over 190,000 shares; significantly reduced ATAT holdings by over 240,000 shares

On Thursday, all three major US stock indices closed higher. The S&P 500 rose 0.65% to close at 7,798.99, the Nasdaq gained 0.81% to 26,803.03, and the Dow Jones Industrial Average edged up 0.13% to 53,839.99. Technology and growth stocks continued to lead the market.

Amid a general market recovery, ARK focused its buying power on core disruptive innovation sectors such as blockchain financial infrastructure, AI computing power, and precision medicine. Meanwhile, it rebalanced positions in certain biotech stocks and high-market-cap targets with significant gains to optimize the portfolio's overall risk-return ratio.

Buy Direction: Increase exposure to blockchain financial infrastructure, AI computing power, and precision medicine

$Securitize (SECZ.US)$ Securitize saw a substantial increase of 192,702 shares, making it the largest purchase of the day. As a core infrastructure provider for digital asset securitization and private market tokenization, Securitize directly benefits from the accelerating influx of institutional capital into blockchain finance. This may well be a key strategic move within ARK's "Fintech Disruption" theme.

$Freenome (FRNM.US)$ Saw an increase of 123,842 shares. Freenome focuses on early cancer screening technology based on liquid biopsy, aligning with ARK's long-term bullish view on the precision medicine and early diagnosis sectors. This addition likely reflects ARK's continued confidence in the commercialization progress of its technology platform.

$Cerebras Systems (CBRS.US)$ Saw an increase of 106,941 shares. Cerebras holds a unique position in the high-performance AI computing sector with its large-wafer AI chip architecture. As demand for AI inference continues to explode, ARK's addition may aim to capture long-term growth opportunities in AI infrastructure hardware.

$Cerus (CERS.US)$ Saw an increase of 69,667 shares. Cerus provides innovative solutions for blood safety through its pathogen inactivation technology, belonging to a niche segment of medical innovation. This increase may be part of ARK's continued deepening of its layout in the biomedical sector.

$Schrodinger (SDGR.US)$ Saw an increase of 28,179 shares. Schrödinger combines computational physics with AI for drug discovery, representing a typical target under ARK's "AI + Life Sciences" theme. This slight addition may reflect ARK's recognition of its long-term platform value.

3iQ Solana Staking ETF (SOLQ.U.US) saw an increase of 10,824 shares. Against the backdrop of a continuously improving regulatory environment for crypto assets, ARK's continued accumulation of Solana-related ETFs suggests a strategic allocation to the long-term value of the high-performance public chain ecosystem.

Sell side: Reduced holdings in biotechnology and some large-cap targets to adjust portfolio structure.

$AtaiBeckley (ATAI.US)$ Saw a significant reduction of 241,388 shares, making it the largest sell-off of the day. Atai Life Sciences (formerly Beckley) is deeply engaged in innovative drug R&D in the mental health field. This substantial reduction in position may reflect ARK's reassessment of its short-term R&D progress and commercialization pace, or possibly the need for portfolio rebalancing.

$Shopify (SHOP.US)$ Saw a reduction of 57,045 shares. As a leader in e-commerce infrastructure, Shopify has shown strong stock performance recently. ARK's reduction may represent active management of position concentration, potentially reallocating funds to targets with more attractive valuations.

$10x Genomics (TXG.US)$ Saw a reduction of 51,171 shares. 10x Genomics is a key player in single-cell sequencing and spatial genomics. This reduction may reflect ARK's structural adjustment of genomics targets within the portfolio, not necessarily indicating a change in its view on their long-term technological roadmap.

$Palantir (PLTR.US)$ Reduced by 43,874 shares. Palantir's valuation has expanded significantly this year. ARK's moderate reduction is likely a position management move targeting high-valuation AI data analytics stocks, aiming to lower the portfolio's concentration risk in a single holding.

$Twist Bioscience (TWST.US)$ Reduced by 11,552 shares. Twist Bioscience is a key player in the core赛道 of synthetic biology DNA synthesis. This slight reduction may be a minor position adjustment, possibly related to ARK's overall allocation optimization in the synthetic biology sector.

$Brera Holdings (SLMT.US)$ Reduced by 4,584 shares and $Deere (DE.US)$ Reduced by 985 shares. The scale of the reduction is relatively limited, suggesting it belongs to routine position management or minor rebalancing operations, with technical significance likely outweighing strategic importance.

Futubull's [Smart Money] feature now tracks celebrity portfolio opportunities! Choose from multiple celebrity holdings, follow the moves of top investors with one click, precisely target high-quality assets, and invest with greater confidence!

97K Views